Onyx Pharmaceuticals is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated®. Our lead product is Nexavar® (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals.

Nexavar is approved in more than 70 countries worldwide for the treatment of patients with advanced kidney cancer, and in more than 60 countries for the treatment of patients with liver cancer. As part of a broad development program, Nexavar is also currently being evaluated in randomized trials in non-small cell lung cancer, breast cancer, and other cancers. We also have a small molecule cell cycle inhibitor in clinical testing that resulted from a collaboration with Pfizer, which is responsible for developing the drug.

For questions about Nexavar treatment, reimbursement, and patient support, please call 1-866-NEXAVAR (1-866-639-2827) or 1.87.REACH.4.IT (1.877.322.4448).

LATEST WEBCAST

Goldman Sachs 30th Annual Global Healthcare Conference
Replay available through July 9, 2009